ArticleVeterinary dermatology2026
Microarray Gene Expression Analysis of Lesional Skin in Canine Vesicular Cutaneous Lupus Erythematosus (VCLE).
Article in Veterinary dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microarray Gene Expression Analysis of Lesional Skin in Canine Vesicular Cutaneous Lupus Erythematosus (VCLE).Veterinary dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVesicular cutaneous lupus erythematosus (VCLE) is a rare autoimmune disease in dogs and is considered the canine counterpart of human subacute cutaneous lupus erythematosus (SCLE). However, the molecular mechanisms underlying VCLE remain incompletely defined. OBJECTIVE/HYPOTHESIS: To characterise gene expression changes in lesional skin from dogs with VCLE and identify immune pathways involved in disease pathogenesis. ANIMALS: Six client-owned dogs with clinically and histopathologically confirmed VCLE, and five healthy control dogs. MATERIALS AND
methodsFormalin-fixed, paraffin-embedded lesional and control skin samples were analysed using the NanoString nCounter Canine Immuno-Oncology Panel, targeting 780 immune-related genes. Data were normalised using geNorm-selected housekeeping genes. Differential expression, cell type profiling and pathway enrichment analyses were also performed.
resultsPrincipal component analysis showed clear separation between VCLE and healthy control samples. A total of 491 differentially expressed genes were identified, including 439 upregulated and 52 downregulated genes (p-adj < 0.05). Lesional skin showed marked upregulation of interferon-stimulated genes (CXCL10, IDO1, ISG15, IFIT1), cytotoxic molecules (GZMB, PRF1, FASLG), pro-inflammatory chemokines (CXCL8, CCL3, CCL4) and S100 family markers (S100A12, S100A9, S100A8). Downregulated genes included DLA-DQB1, ERBB4, CCL27, GATA3 and RORC. Cell type profiling demonstrated enrichment of CD8 CONCLUSIONS AND CLINICAL RELEVANCE: VCLE lesions feature a dominant interferon-stimulated gene signature, with downstream activation of JAK-STAT signalling and cytotoxic lymphocyte-mediated immune responses, suggesting that interferon and JAK-STAT signalling are potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.